China will begin to test a possible COVID-19 vaccine candidate produced by a Germany-based BioNTech firm, whose founder and CEO is Turkish scientist Ugur Sahin, APA reports citing Yeni Safak.
According to Clinical Trials Arena, a website focused on reporting drug development and research process, China’s National Medical Products Administration (NMPA) accepted an application submitted by Shanghai Fosun Pharmaceutical’s unit Fosun Pharmaceutical Industrial for a trial of COVID-19 vaccine candidate, BNT162b1.
“Fosun Pharma obtained license for the vaccine candidate from German company BioNTech to exclusively develop and commercialize the product in China,” the website reported.
“Based on BioNTech’s mRNA technology platform, the vaccine candidate is a prophylactic biological product intended to protect individuals aged 18 and above from Covid-19,” the report added.
The vaccine candidate is already undergoing COVID-19 clinical trials in Germany and the US.